SCHEMBL4469790

SCHEMBL4469790

CCc1cc(C2C(C)OC(=O)N2C)ccc1-c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.35
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
GRM2 Q14416 2/20 0.32
ATM Q13315 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
POLB P06746 1/20 0.31
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4454827 0.85 ESR2 (0.39) HSD17B10KDM4EPDE4APDE4BPDE4C
SCHEMBL4460630 0.84 GRM2 (0.41) HSD17B10GRM2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4458127 0.84 GRM2 (0.38) HSD17B10GRM2LMNAPDE3BPDE3A
SCHEMBL4447352 0.84 GRM2 (0.37) HSD17B10GRM2ALDH1A1KDM4EMEN1
SCHEMBL4445385 0.82 PGR (0.40) HSD17B10GRM2ATMSMN1; SMN2NPSR1
SCHEMBL4474719 0.81 PDE3B (0.39) PDE3BPDE3A
SCHEMBL4453552 0.81 BRD4 (0.35) PTGDR2HTTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL4445299 0.80 ALDH1A1 (0.39) HTTHSD17B10SMN1; SMN2ALDH1A1LMNA
SCHEMBL4472192 0.79 GRM2 (0.35) PTGDR2GRM2PDE3BPDE3A
SCHEMBL9926818 0.76 TSHR (0.46) ATMSMN1; SMN2NPSR1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137577-A1 HETEROCYCLIC COMPOUNDS PFIZER INC. 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137577-A1 HETEROCYCLIC COMPOUNDS CYP2D6, ABCG2, CYP2B6 PTGDR2 685/4885HTT 915/4885HSD17B10 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.